Lafutidine | 118288-08-7

Lafutidine Properties

Melting point	92.7-94.9°
Boiling point	704.2±60.0 °C(Predicted)
Density	1.252±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Water Solubility	Insoluble in water
solubility	DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM) DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM) DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM) Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM)
form	powder to crystal
pka	13.13±0.46(Predicted)
color	White to Orange to Green
InChIKey	KMZQAVXSMUKBPD-DJWKRKHSSA-N
SMILES	C(NC/C=C\COC1=NC=CC(CN2CCCCC2)=C1)(=O)CS(CC1=CC=CO1)=O
CAS DataBase Reference	118288-08-7(CAS DataBase Reference)
FDA UNII	49S4O7ADLC
ATC code	A02BA08
UNSPSC Code	12352200
NACRES	NA.77

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H302-H315-H319-H335

Precautionary statements

P261-P305+P351+P338

Safety Statements

24/25

HS Code

29349990

NFPA 704

	0
1		0

Lafutidine price More Price(43)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Sigma-Aldrich	SML1611	Lafutidine ≥98% (HPLC)	118288-08-7	10 mg	$91.67	2025-07-31	Buy
Sigma-Aldrich	SML1611	Lafutidine ≥98% (HPLC)	118288-08-7	50 mg	$182	2025-07-31	Buy
TCI Chemical	L0341	Lafutidine	118288-08-7	25MG	$16	2025-07-31	Buy
TCI Chemical	L0341	Lafutidine	118288-08-7	1G	$266	2025-07-31	Buy
Cayman Chemical	30275	Lafutidine	118288-08-7	25mg	$44	2024-03-01	Buy

Product number	Packaging	Price	Buy
SML1611	10 mg	$91.67	Buy
SML1611	50 mg	$182	Buy
L0341	25MG	$16	Buy
L0341	1G	$266	Buy
30275	25mg	$44	Buy

Lafutidine Chemical Properties,Uses,Production

Description

Lafutidine is a second generation of H2-receptor antagonist. H2-receptor antagonist can strongly inhibit gastric acid secretion compared with conventional drugs such as antacids. Unlike conventional H2-receptor antagonist, lafutidine inhibits gastric acid secretion during daytime as well as nighttime in clinical studies in humans. Lafutidine also has gastroprotective activity independent of its acid antisecretory efficacy, preventing noxious agent-induced gastric mucosal injury and accelerating the repair process following gastric mucosal damage. It also protects experimentally induced reflux esophagitis, indomethacin-induced intestinal, and dextran sulfate sodium-induced colonic inflammation.
Lafutidine is used for gastric and duodenal ulcers. It is also confirmed that lafutidine can be used as an empiric treatment and superior efficacy for primary care practice patients with dyspepsia.

References

[1] Tomohiko Shimatani, Masaki Inoue, Tomoko Kuroiwa, Jing Xu, Masuo Nakamura, Susumu Tazuma, Kazuro Ikawa, Norifumi Morikawa (2006) Lafutidine, a Newly Developed Antiulcer Drug, Elevates Postprandial Intragastric pH and Increases Plasma Calcitonin Gene-Related Peptide and Somatostatin Concentrations in Humans: Comparisons with Famotidine, Digestive Diseases and Sciences, 51, 114-120
[2] Bhupesh Dewan, Nisha Philipose (2011) Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial, Gastroenterology Research and Practice, 2011, Article ID 640685
[3] https://www.drugs.com

Description

Lafutidine was launched in Japan for the treatment of gastritis, reflux oesophagitis and peptic ulcers. It can be prepared in eight steps from 4-(2-tetrahydropyranyloxy)-2(Z)-butenl- ol. Lafutidine is a potent and longer-acting H₂ antagonist compared to other marketed compounds of its class such as cimetidine and famotidine. In contrast to other commercially available H₂ antagonists, lafutidine also exerts a gastroprotective action probably via capsaicin-sensitive afferent nerves. It was clinically effective in the treatment of nonsteroidal antiinflammatory drug-induced ulcer in patients refractory to existing antiulcer agents.

Description

Lafutidine is a histamine H₂ receptor antagonist with gastroprotective activity. It inhibits histamine-induced cAMP production in CHO cells expressing human histamine H₂ receptors when used at a concentration of 10 nM. Intragastric administration of lafutidine (3, 10, and 30 mg/kg) reduces hemorrhagic esophageal lesion size and gastric acid secretion in a rat model of pyloric ligation-induced reflux esophagitis. It prevents 5-fluorouracil-induced intestinal mucositis, diarrhea, and body weight loss in wild-type, but not Trpv1^-/- or sensory deafferented, mice when administered at doses ranging from 3 to 30 mg/kg. Lafutidine (10 mg/kg) also reduces indomethacin-induced antral ulcer size in wild-type, but not chemically-deafferented, rats.

Originator

Fujirebio (Japan)

Uses

(Z)-2-((Furan-2-ylmethyl)sulfinyl)-n-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide is a Histaminic H2 receptor antagonists in ulcer disease. Also, it is a model compound used to investigate the binding mechanism between antiulcer drugs and human serum albumin (HSA).

Uses

Second generation histamine H2-receptor antagonist. Antiulcerative

Uses

Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion

Definition

ChEBI: Lafutidine is an organic molecular entity.

brand name

Stogar, Protecadin

References

[1] Y. FUKUSHIMA. Potent and Long-Lasting Action of Lafutidine on the Human Histamine H2 Receptor[J]. Digestion, 2001, 64 1: 155-160. DOI: 10.1159/000048856
[2] KENJI NAGAHAMA. Protective effect of lafutidine, a novel H2-receptor antagonist, on reflux esophagitis in rats through capsaicin-sensitive afferent neurons.[J]. Journal of pharmacological sciences, 2003, 93 1: 55-61. DOI: 10.1254/jphs.93.55
[3] T SANO. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.[J]. Journal of Physiology and Pharmacology, 2017, 68 1: 79-90.
[4] S ONODERA. Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity.[J]. Arzneimittel-Forschung-Drug Research, 1999, 49 6: 519-526. DOI: 10.1055/s-0031-1300454

Lafutidine synthesis

Synthesis of Lafutidine from 118289-22-8

Lafutidine Preparation Products And Raw materials

Raw materials

Pyridine, 4-(1-piperidinylmethyl)-2-[[(2Z)-4-[(tetrahydro-2H-pyran-2-yl)oxy]-2-buten-1-yl]oxy]- 118289-23-9 2-(4-((4-(1,3-dioxolan-2-yl)pyridin-2-yl)oxy)but-2-en-1-yl)isoindoline-1,3-dione 118287-95-9 118289-22-8

4-((4-(1,3-dioxolan-2-yl)pyridin-2-yl)oxy)but-2-en-1-ol 4-(1,3-dioxolan-2-yl)-2-((4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-en-1-yl)oxy)pyridine Piperidine

1of2

Preparation Products

Lafutidine Suppliers

Global( 334)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
Moxin Chemicals	+8617320513646	Anna@molcoo.com	China	9893	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21622	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
career henan chemical co	+86-0371-86658258 +8613203830695	sales@coreychem.com	China	29855	58
Jinan Shengqi pharmaceutical Co,Ltd	86+18663751872	christine@shengqipharm.com	CHINA	491	58
Hubei Jusheng Technology Co.,Ltd.	18871490254	linda@hubeijusheng.com	CHINA	28172	58
HubeiwidelychemicaltechnologyCo.,Ltd	18627774460	faith@widelychemical.com	CHINA	742	58
Alchem Pharmtech,Inc.	8485655694	sales@alchempharmtech.com	United States	63687	58
Shanghai Yingrui Biopharma Co.,Ltd	21-33585366	export01@shyrchem.com	CHINA	1319	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	49975	58

Supplier	Advantage
Moxin Chemicals	58
Henan Tianfu Chemical Co.,Ltd.	55
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
Jinan Shengqi pharmaceutical Co,Ltd	58
Hubei Jusheng Technology Co.,Ltd.	58
HubeiwidelychemicaltechnologyCo.,Ltd	58
Alchem Pharmtech,Inc.	58
Shanghai Yingrui Biopharma Co.,Ltd	58
CONIER CHEM AND PHARMA LIMITED	58

View Lastest Price from Lafutidine manufacturers

Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
2025-09-15	Lafutidine 118288-08-7			0.99		RongNa Biotechnology Co.,Ltd
2025-09-15	Lafutidine 118288-08-7	US $0.00 / Kg/Bag	10g	98.5%min	10kg	WUHAN FORTUNA CHEMICAL CO., LTD
2025-09-15	Lafutidine 118288-08-7	US $66.00-41.00 / mg		100.00%	10g	TargetMol Chemicals Inc.

Lafutidine
118288-08-7
0.99
RongNa Biotechnology Co.,Ltd

Lafutidine
118288-08-7
US $0.00 / Kg/Bag
98.5%min
WUHAN FORTUNA CHEMICAL CO., LTD

Lafutidine
118288-08-7
US $66.00-41.00 / mg
100.00%
TargetMol Chemicals Inc.

Lafutidine Spectrum

Lafutidine(118288-08-7)¹HNMR

118288-08-7(Lafutidine)Related Search:

Omeprazole Famotidine Ranitidine Lafutidine N-{4-[4-(PIPERIDINOMETHYL)PYRIDYL-2-OXY]-CIS-2-BUTENE}PHTHALIMIDE MALEIC ACID(INTERMEDIATE FOR LAFUTIDINE)

LACTITOL MONOHYDRATE,LACTITOL H2O,D-LACTITOL MONOHYDRATE,LACTITOL MONOHYDRATE 99% p-Nitrophenyl 2-(Furfurylsulfinyl)acetate 4-[4-(Piperidinomethyl)pyridyl-2-oxy]-cis-2-butenamine 2-ALLYLOXYPYRIDINE LACTITOL

(Z)-4-[(TETRAHYDRO-2H-PYRAN-2-YL)OXY]-2-BUTEN-1-OL (PREPARATION FOR LAFUTIDINE) Lomerizine Furan Acetamide 2-Butene

2(1H)-Pyridinone,4-(aminomethyl)-(9CI) 2-((FURAN-2-YL)METHYLSULFINYL)-N-((Z)-4-HYDROXYBUT-2-ENYL)ACETAMIDE N-(PYRIDIN-4-YLMETHYL)BUTAN-1-AMINE

1of4

n-(4-(4-piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide 2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((4-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide (Z)-2-((Furan-2-ylMethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylMethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetaMide Adefovir Dipivioxil (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl) (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1- LAFUTIDINE(SUBJECTTOPATENTFREE) 118288-08-07 LACTITOL 2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]acetamide Laflutidine Protecadin Stogar 2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)4-[[4-(1-piperidinylmethyl)-2-pyridinyl] oxy]-2-butenyl]-acetamide LAFUTIDINE (+-)-2-(furfurylsulfinyl)-n-(4-(4-(piperidinomethyl)-2-pyridyl)oxy-(z)-2-but (z)-inyl)oxy)-2-butenyl) acetamide,2-((2-furanylmethyl)sulfinyl)-n-(4-((4-(1-piperidinylmethyl)-2-pyrid enyl)acetamide frg-8813 2-(2-furanylmethylsulfinyl)-N-[2-hydroxy-4-[4-(4-piperidinylmethyl)-2-pyridinyl]but-1-enyl]acetamide Lafutidine Lafutidine (Z)-2-[(Furan-2-ylmethyl)sulfinyl]-N-[4-[[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy]but-2-en-1-yl]acetamide Lafutidine USP/EP/BP 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide (+)-(Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((4-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide Lafutidine (FRG-8813) LafutidineQ: What is Lafutidine Q: What is the CAS Number of Lafutidine Q: What is the storage condition of Lafutidine Q: What are the applications of Lafutidine Lafutidine API R)-Palonosetron Hydrochloride Lafutidine Tablets Lafurtidine Lafutidine, 10 mM in DMSO 118288-08-7 118288-89-7 118288-08-07 118288-08-1 18288-08-7 C22H29N3O4S Other APIs Active Pharmaceutical Ingredients Heterocycles Intermediates & Fine Chemicals Pharmaceuticals Sulfur & Selenium Compounds